EuBiologics Co., Ltd. (KOSDAQ: 206650)

Market Cap	433.66B
Revenue (ttm)	69.37B
Net Income (ttm)	-13.88B
Shares Out	36.53M
EPS (ttm)	-381.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	206,935
Open	12,300
Previous Close	12,580
Day's Range	12,070 - 12,360
52-Week Range	9,350 - 18,800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 27, 2025

About EuBiologics

EuBiologics Co., Ltd., a biopharmaceutical company, provides vaccines for epidemics in South Korea. It offers Euvichol Plus, an oral cholera prevention vaccine; and rCRM197, a diphtheria toxoid vaccine. The company also provides EcML, a vaccine for cell membrane, as well as offers COVID-19 diagnostic kits. In addition, it offers CMO services comprising of drug product production, cell bank production, and drug substance production. Further, the company provides CRMO services, including cell line development, GMP production, validation, and the ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 206650

Financial Performance

In 2023, EuBiologics's revenue was 69.37 billion, an increase of 25.06% compared to the previous year's 55.47 billion. Losses were -13.88 billion, 1163.0% more than in 2022.